Aardvark Therapeutics (AARD) Stock Chart & Stock Price History $11.20 +1.16 (+11.55%) As of 04:00 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Aardvark Therapeutics Stock Price Performance The Aardvark Therapeutics (AARD) stock chart highlights key performance trends across multiple timeframes. In the past month, the stock has decreased 7.97%, reflecting recent market activity. As of the latest close, Aardvark Therapeutics traded at $10.04 with a market cap of $217.87 million and volume of 146,871 shares. Receive AARD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-6.59%1 Month Performance-7.97%3 Month Performance+10.45% AARD Stock Chart for Wednesday, August, 13, 2025 AARD Chart by TradingView Aardvark Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/12/2025$11.15$10.04-9.96%$11.28$9.75146,871 shs$217.87 million08/11/2025$11.99$11.15-7.01%$12.41$10.7673,947 shs$241.91 million08/08/2025$11.97$11.99+0.17%$12.50$11.5025,018 shs$260.14 million08/07/2025$12.57$11.97-4.77%$13.24$11.5536,051 shs$259.75 million08/06/2025$12.55$12.57+0.16%$13.18$12.1413,608 shs$272.77 million08/05/2025$12.50$12.55+0.40%$12.66$11.9917,392 shs$272.29 million08/04/2025$12.13$12.50+3.05%$13.63$12.0220,176 shs$271.25 million08/01/2025$12.01$12.13+1.00%$12.55$11.5036,180 shs$263.22 million07/31/2025$12.69$12.01-5.36%$12.88$12.0131,497 shs$260.62 million07/30/2025$12.98$12.69-2.23%$14.30$12.4026,277 shs$275.32 million Get the Latest News and Ratings for AARD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/29/2025$13.58$12.98-4.42%$13.62$12.9028,079 shs$281.67 million07/28/2025$14.70$13.58-7.62%$15.01$13.3234,585 shs$294.69 million07/25/2025$13.47$14.70+9.13%$15.17$13.5638,646 shs$318.99 million07/24/2025$14.23$13.47-5.34%$13.94$13.3328,800 shs$292.30 million07/23/2025$13.75$14.23+3.49%$14.65$13.7529,347 shs$308.73 million07/22/2025$12.00$13.75+14.58%$14.16$12.1050,567 shs$298.38 million07/21/2025$11.62$12.00+3.27%$12.19$11.5180,726 shs$260.40 million07/18/2025$11.96$11.62-2.84%$12.11$11.3471,052 shs$252.15 million07/17/2025$11.60$11.96+3.10%$12.07$11.0937,085 shs$259.48 million07/16/2025$11.61$11.60-0.09%$12.06$11.5337,432 shs$251.72 million07/15/2025$12.11$11.61-4.13%$12.20$11.2240,020 shs$251.89 million07/14/2025$12.17$12.11-0.49%$12.58$11.6560,803 shs$262.74 million Related Companies VERV Stock Price Chart LENZ Stock Price Chart PRAX Stock Price Chart RCUS Stock Price Chart AVXL Stock Price Chart GPCR Stock Price Chart SYRE Stock Price Chart CRON Stock Price Chart ELVN Stock Price Chart AKBA Stock Price Chart Receive AARD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:AARD) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access